New Acute Myeloid Leukemia (AML) Drug, Voreloxin, Looks Promising To Investors

I like to watch Internet business sites for cancer drug company news:
BOSTON (MarketWatch) — by By Val Brickates Kennedy
Drug stocks were sluggish in early trading Thursday, while shares of Sunesis Pharmaceuticals soared on the publication of a favorable study for its leukemia drug candidate voreloxin in a leading medical journal. Sunesis shares shot up almost 20% to $1.50. Sunesis said that a laboratory study of voreloxin showed the compound was effective in attacking leukemia cells. The biotech group plans to begin Phase III testing of voreloxin in the treatment of acute myeloid leukemia, or AML, later this year.
Rising stock prices for a particular company can be misleading. However, you know the old saying: “Follow the money!” Financial reports like this one can be good news–only time will tell.

Feel good and keep smiling! Pat

Liked this article? Share it! Information is power!

• 

acute myeloid leukemia, AML, sunesis pharmaceuticals, voreloxin